Cannon Global Investment Management LLC Buys New Shares in uniQure N.V. $QURE

Cannon Global Investment Management LLC acquired a new stake in shares of uniQure N.V. (NASDAQ:QURE) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 12,200 shares of the biotechnology company’s stock, valued at approximately $199,000.

Several other large investors have also made changes to their positions in QURE. Avoro Capital Advisors LLC raised its holdings in uniQure by 38.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after buying an additional 1,705,556 shares during the period. Aberdeen Group plc boosted its stake in uniQure by 25.1% during the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after acquiring an additional 738,897 shares during the last quarter. State Street Corp lifted its position in shares of uniQure by 123.8% during the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after purchasing an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after buying an additional 1,785,275 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in uniQure by 23.9% during the third quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock worth $116,073,000 after purchasing an additional 383,066 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Stock Down 3.2%

QURE opened at $47.51 on Friday. The company has a market capitalization of $3.00 billion, a PE ratio of -13.65 and a beta of 0.98. The business has a 50-day moving average of $27.84 and a 200-day moving average of $23.02. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. Equities research analysts forecast that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on QURE shares. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. The Goldman Sachs Group upped their price objective on shares of uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday, June 18th. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Chardan Capital raised their price objective on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Finally, Sanford C. Bernstein cut uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $61.67.

Insider Transactions at uniQure

In other news, Director David D. Meek sold 1,993 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the sale, the director directly owned 39,747 shares of the company’s stock, valued at approximately $1,075,553.82. This trade represents a 4.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jack Kaye sold 5,295 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $42.57, for a total value of $225,408.15. Following the completion of the sale, the director directly owned 25,996 shares in the company, valued at $1,106,649.72. This trade represents a 16.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 359,546 shares of company stock worth $14,549,943. 4.65% of the stock is currently owned by company insiders.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.